IL229723A0 - Human fusion proteins including interferons and modified targeted ubiquitin proteins - Google Patents

Human fusion proteins including interferons and modified targeted ubiquitin proteins

Info

Publication number
IL229723A0
IL229723A0 IL229723A IL22972313A IL229723A0 IL 229723 A0 IL229723 A0 IL 229723A0 IL 229723 A IL229723 A IL 229723A IL 22972313 A IL22972313 A IL 22972313A IL 229723 A0 IL229723 A0 IL 229723A0
Authority
IL
Israel
Prior art keywords
proteins
trageted
interferons
modified ubiquitin
human fusion
Prior art date
Application number
IL229723A
Other languages
English (en)
Hebrew (he)
Original Assignee
Scil Proteins Gmbh
Steuernagelarnd
Nerkampjorg
Langechristain
Glosermanja
Parthierantje
Hanssgen Ilka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scil Proteins Gmbh, Steuernagelarnd, Nerkampjorg, Langechristain, Glosermanja, Parthierantje, Hanssgen Ilka filed Critical Scil Proteins Gmbh
Publication of IL229723A0 publication Critical patent/IL229723A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL229723A 2011-06-15 2013-11-28 Human fusion proteins including interferons and modified targeted ubiquitin proteins IL229723A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2011/002962 WO2012171541A1 (en) 2011-06-15 2011-06-15 Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
PCT/EP2012/061459 WO2012172058A1 (en) 2011-06-15 2012-06-15 Human fusion proteins comprising interferons and targeted modified ubiquitin proteins

Publications (1)

Publication Number Publication Date
IL229723A0 true IL229723A0 (en) 2014-01-30

Family

ID=46354263

Family Applications (1)

Application Number Title Priority Date Filing Date
IL229723A IL229723A0 (en) 2011-06-15 2013-11-28 Human fusion proteins including interferons and modified targeted ubiquitin proteins

Country Status (6)

Country Link
US (1) US20140219959A1 (enExample)
JP (1) JP2014523238A (enExample)
AU (1) AU2012268973A1 (enExample)
CA (1) CA2837875A1 (enExample)
IL (1) IL229723A0 (enExample)
WO (2) WO2012171541A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2721152B1 (en) 2011-06-15 2019-03-27 Navigo Proteins GmbH Dimeric binding proteins based on modified ubiquitins
WO2014094799A1 (en) * 2012-12-19 2014-06-26 Scil-Proteins-Gmbh Ubiquitin moieties as a means for prolonging serum half-life
JP6738340B2 (ja) 2015-02-06 2020-08-12 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ 新規なｅｇｆｒ結合タンパク質
ES2916101T3 (es) 2015-07-16 2022-06-28 Navigo Proteins Gmbh Nuevas proteínas de unión a inmunoglobulina y su uso en la purificación por afinidad
JP2018520675A (ja) 2015-07-20 2018-08-02 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法
JP2019526526A (ja) 2016-05-04 2019-09-19 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ペプチドリンカーを含む化学的部分の部位特異的カップリングのための標的化合物
DK3497117T5 (da) 2016-08-11 2024-09-02 Navigo Proteins Gmbh Nye alkalisk stabile immunglobulin-bindende proteiner
CA3062591A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
EP3706804B1 (en) 2017-11-07 2022-02-23 Navigo Proteins GmbH Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
JP7653013B2 (ja) 2018-01-04 2025-03-28 アイコニック セラピューティクス リミテッド ライアビリティ カンパニー 抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法
WO2019136552A1 (en) * 2018-01-11 2019-07-18 Uti Limited Partnership Treatment of fragile x syndrome
CN108727504B (zh) * 2018-04-16 2021-08-27 泉州向日葵生物科技有限公司 一种ifn与抗pd-l1抗体的融合蛋白及其应用
AU2020271959B2 (en) * 2019-04-10 2022-09-29 Navigo Proteins Gmbh Novel PSMA specific binding proteins for cancer diagnosis and treatment
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
US20220323546A1 (en) * 2020-04-20 2022-10-13 Altum Pharmaceuticals Inc. Recombinant interferon
WO2021217113A1 (en) * 2020-04-25 2021-10-28 East Carolina University Compositions and methods of treating a coronavirus infection by use of an interferon fusion protein
CA3187258A1 (en) 2020-08-06 2022-02-10 Karin Jooss Multiepitope vaccine cassettes
WO2022232015A1 (en) * 2021-04-26 2022-11-03 East Carolina University Compositions and methods of treating pathogenic infections by using fusion proteins
WO2023239213A1 (ko) * 2022-06-10 2023-12-14 주식회사 쎌트로이 염증세포에서 특이적으로 작동하는 융합단백질

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5789166A (en) 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
CA2399866C (en) 2000-02-24 2011-05-10 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
EP1259548A1 (en) 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
DE10324447A1 (de) * 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
DE10360483B4 (de) 2003-12-22 2007-11-15 Scil Proteins Gmbh Expressionsvektor und dessen Verwendung
DE102004049479A1 (de) 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
CA2607954A1 (en) 2005-05-11 2006-11-16 Philogen S.P.A. Conjugate for targeting of drug
BRPI0520677A2 (pt) 2005-11-09 2009-05-19 Bayer Schering Pharma Ag identificação e caracterização de anticorpos de função de bloqueio anti-ed-b-fibronectina
EP1842553A1 (en) 2006-04-07 2007-10-10 Bayer Schering Pharma Aktiengesellschaft Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule
JP2009536170A (ja) 2006-05-08 2009-10-08 フィロジェン・エッセペア 治療用の抗体標的指向サイトカイン
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
AU2009233925B2 (en) * 2006-12-05 2014-03-13 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
BR112012014194A2 (pt) 2009-12-14 2017-01-10 Scil Proteins Gmbh um método para identificar proteínas ubiquitinas modificadas hetero-multiméricas com capacidade de ligação a ligandos

Also Published As

Publication number Publication date
CA2837875A1 (en) 2012-12-20
WO2012172058A1 (en) 2012-12-20
AU2012268973A1 (en) 2013-12-12
US20140219959A1 (en) 2014-08-07
WO2012171541A1 (en) 2012-12-20
JP2014523238A (ja) 2014-09-11

Similar Documents

Publication Publication Date Title
IL229723A0 (en) Human fusion proteins including interferons and modified targeted ubiquitin proteins
IL286784A (en) Compositions of protein and antibody
IL230918A0 (en) Modified proteins and peptides
IL279676A (en) Recombinant proteins and therapeutic uses
ZA201308465B (en) Modified biotin-binding protein fusion proteins thereof and applications
IL236809A0 (en) Interleukin-10 fusion proteins and their use
IL229753A0 (en) Proteins that release relaxin and their use
IL236933A0 (en) Interleukin-2 fusion proteins and their use
PT3434775T (pt) Proteína que tem atividade de nuclease, proteínas de fusão e utilizações das mesmas
IL232073A0 (en) Recombinant human naglu protein and its uses
SG10201601621PA (en) Serpin fusion polypeptides and methods of use thereof
LT2776460T (lt) Sulietas baltymas, apimantis interleukiną-4 ir interleukiną-10
ZA201400562B (en) Axmi205 variant proteins and methods for their use
EP2797629A4 (en) AGLYCOSYLATED HUMAN ANTIBODY AND FUSION PROTEIN AND USES THEREOF
DK3173102T3 (da) FGFR-FC-fusionsprotein og anvendelse deraf
PL2668205T3 (pl) Peptydy pochodzące z ludzkiej laktoferyny i ich zastosowanie
EP2718432A4 (en) NUCLEASE FUSION PROTEIN AND USES THEREOF
GB201121233D0 (en) Modified proteins and peptides
GB201121226D0 (en) Modified proteins and peptides
GB201121236D0 (en) Proteins and peptides
AU2011902431A0 (en) Fusion Proteins and Use Thereof
HK1192893A (en) Modified proteins and peptides
AU2012901619A0 (en) Fusion Proteins and Use Thereof